EBV-DNA-Guided Adaptive Immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EBV-DNA-Guided Adaptive Immunotherapy, covering 2025-11-20 to 2025-11-20. Get the full timeline:
Most recent: Clinical Trial Update: Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma [Phase 3]